Endpoints’ 10 biggest stories of 2022
November 28, 2022
The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies
Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs
‘Go quickly’: Amgen R&D vet Dirk Nagorsen jumps to a startup with big plans for TCRs
No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field
Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors
A new cell therapy startup from an immunotherapy pioneer raises $175M in KRAS quest
Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field
Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, and his former employer is ready to dole it out. Led by Vida Ventures […]
Affini-T Therapeutics launches with $175 million for cancer treatments
The startup, based in Boston and Seattle, will make T cell therapies for infamously tough-to-treat conditions.
Vida, Bayer throw weight behind $175M T-cell startup
Affini-T Therapeutics has formally launched with $175 million in venture capital, one clinical-stage drug licensed from Fred Hutch and two more solid tumor-targeting drugs that should enter the clinic next year.